Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer
Launched by SCRI DEVELOPMENT INNOVATIONS, LLC · Sep 12, 2005
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
Upon determination of eligibility, all patients will be receive:
Gemcitabine + Epirubicin + Docetaxel
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- To be included in this study, you must meet the following criteria:
- • Adenocarcinoma of the breast confirmed by biopsy
- • Female Patients \>18 years of age
- • Normal cardiac function
- • Ability to perform activities of daily living with minimal assistance
- • Chemotherapy naïve or have received prior chemotherapy \> 5 years ago
- • Adequate bone marrow, liver and kidney function
- • Be informed of the investigational nature of this study
- • Sign an informed consent form
- • Sentinel lymph node and/or axillary dissection prior to enrollment
- Exclusion Criteria:
- You cannot participate in this study if any of the following apply to you:
- • Life expectancy of \< than 6 months
- • History of significant heart disease
- • Prior chemotherapy or hormonal therapy
- • Concurrent Trastuzumab therapy
- • History of significant psychiatric disorders
- • History of active uncontrolled infection
- • Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
About Scri Development Innovations, Llc
SCRI Development Innovations, LLC is a leading clinical trial sponsor dedicated to advancing medical research through innovative trial design and execution. With a focus on oncology and other therapeutic areas, the organization collaborates with a network of clinical sites, researchers, and healthcare professionals to ensure the efficient and ethical conduct of clinical studies. SCRI Development Innovations leverages cutting-edge technology and data analytics to optimize patient recruitment and retention, ultimately striving to bring new therapies to market that improve patient outcomes and enhance the quality of care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Denise A. Yardley, MD
Principal Investigator
SCRI Development Innovations, LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials